Marinus cuts 45% of staff after key medicine stumbled in pair of phase 3 trials

Last month, a second phase 3 blow for Marinus Pharmaceuticals prompted the Pennsylvania-based drugmaker to turn an eye toward layoffs and scrap further development of its flagship seizure med. Now, Marinus says it's moving toward a potential refractory status epilepticus (RSE) expansion opportunity with 45% fewer employees.